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Abstract 
IV thrombolysis (rt-PA) for ischemic stroke treatment carries a substantial risk for 
symptomatic intracerebral hemorrhage (sICH) and adverse outcome. Our purpose was to 
develop a computationally simple and accurate clinical predictor of adverse outcome after rt-
PA therapy.   
Our derivation dataset consisted of 210 ischemic stroke patients receiving IV rt-PA 
from January 2009 until July 2013 at Yale New Haven Hospital. Our validation dataset 
included 303 patients who received IV rt-PA during the NINDS rt-PA trial. Predictive ability 
and goodness of fit were quantified by odds ratios (OR) and areas under the receiver 
operating characteristic curve (AUROC). Patient outcomes included sICH, brain swelling, 
90-day severe outcome and 90-day mortality. Severe outcome was defined as 90-day 
modified Rankin Scale (mRS) scores ≥ 5, 90-day Barthel Index (BI) scores < 60 and 90-day 
Glasgow Outcome Scale (GOS) scores > 2. 
Out of seventeen clinical parameters tested, three were independent predictors of 
sICH: prestroke mRS score (OR 1.54, P = 0.02), baseline National Institutes of Health Stroke 
Scale (NIHSS) score (OR 1.13, P = 0.002), and platelet count (OR 0.99, P = 0.04). We 
combined these three parameters to form the TURNP (Thrombolysis risk Using mRS, 
NIHSS and Platelets) score. For added simplicity, prestroke mRS score and baseline NIHSS 
score were also combined to form the TURN (Thrombolysis risk Using mRS and NIHSS) 
score, which predicted sICH without a significant drop in OR or AUROC. TURN predicted 
sICH with AUROC 0.74 (0.58 – 0.90) in the derivation dataset, and AUROC 0.65 (0.54 – 
0.77) in the validation dataset. In the validation dataset, TURN predicted 24-hour brain 
swelling with AUROC 0.69 (0.63 - 0.75), 90-day mRS ≥ 5 with AUROC 0.83 (0.77, 0.89), 
		
90-day BI < 60 with AUROC 0.81 (0.76 – 0.86), 90-day GOS > 2 with AUROC 0.81 (0.76 – 
0.86) and 90-day mortality with AUROC 0.82 (0.76 – 0.88).  
 To improve the clinical utility of TURN, we developed and tested a mobile 
application Risk rtPA based on TURN for predicting 90-day outcome after rt-PA treatment. 
Risk rtPA returned predictions of severe outcome for a range of hypothetical patients with 
varying clinical characteristics, demonstrating broad applicability. This mobile application 
brings computationally simple prediction of post-thrombolysis risk to the bedside for real-
time stroke prognostication.  
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Introduction 
Stroke is the number 4 cause of death and a leading cause of long-term disability in 
the United States 1. Roughly 6.8 million Americans 20 years and older have had a stroke, and 
an additional 4 million individuals are projected to have a stroke by the year 2030 1. About 
780,000 strokes are estimated to occur annually in the United States 2. Risk factors for stroke 
are well established and include family history, high blood pressure, diabetes mellitus, atrial 
fibrillation, high cholesterol, smoking, physical inactivity and chronic kidney disease 1.   
87% of all strokes are ischemic (e.g., due to large artery thrombosis or cardiogenic 
embolism). As a result, much attention has been focused on developing treatment strategies 
for this stroke subtype. However, hemorrhagic strokes (intracerebral or subarachnoid) which 
comprise the other 13% of strokes are more frequently associated with impaired 
consciousness and thus carry increased risk of mortality within the first 3 weeks after stroke 
3. Furthermore, intracerebral hemorrhage may lead to ischemic lesions and worse clinical 
outcomes in up to 25% of cases 4,5. Therefore, hemorrhagic strokes warrant careful 
characterization and development of optimal treatment strategies.  
Hemorrhagic strokes may occur spontaneously, or may be associated with trauma or 
with aneurysm rupture. Additionally, hemorrhage may occur secondarily to an ischemic 
stroke, so-called hemorrhagic transformation (HT), leading to symptomatic intracerebral 
hemorrhage (sICH). sICH is of particular clinical importance because whereas thrombolytic 
therapy (rt-PA) for ischemic stroke decreases stroke mortality, it carries a substantial risk for 
sICH 6. The National Institute of Neurological Diseases and Stroke (NINDS) rt-PA trial 
found that ischemic stroke patients receiving rt-PA therapy within three hours of symptom 
onset were at least 30% more likely to recover with little or no disability after three months, 
		
however up to 6.5% of these patients developed sICH 7. The European Cooperative Acute 
Stroke Study (ECASS) trials extended the rt-PA time window to 4.5 hours, but confirmed a 
risk for sICH after thrombolysis (8.8% sICH in ECASS II and 2.4% in ECASS III) 8-10.  
As a result of these studies, anticoagulant and thrombolytic treatment is 
contraindicated in patients with hemorrhage, and risk of sICH must be considered when 
treating any ischemic stroke patient 3. However some subsets of ischemic stroke patients such 
as those defined by stringent ECASS exclusion criteria or those with intracranial aneurysms 
may not suffer additional adverse effects from rt-PA therapy 11,12. Yet, the risk of sICH has 
partly hindered broad adoption of rt-PA therapy. A 2005 survey reported that 40% of 
emergency physicians were not likely to use rt-PA, with the risk of sICH cited as the main 
reason in 65% of cases 13. Emergency physicians also reported a mean upper limit of 
tolerable sICH rate of 3.4%, reflecting an increasing demand for wider safety margins for rt-
PA therapy. Further studies are needed to establish safe criteria for thrombolytic therapy.  
The use of rt-PA is also limited by delayed presentation after ischemic stroke. A 
pooled analysis of patients from the ECASS, Alteplase Thrombolysis for Acute 
Noninterventional Therapy in Ischemic Stroke (ATLANTIS), NINDS and Echoplanar 
Imaging Thrombolytic Evaluation Trial (EPITHET) trials found a significant association 
between decreased symptom onset-to-treatment (OTT) duration and favorable 3-month 
outcome 14. Likewise, an analysis of an 80,000-patient cohort in Europe found that early 
treatment was associated with favorable outcome 15. As a result, the American Heart 
Association Science Advisory and Coordinating Committee guidelines emphasize rapid 
recognition of stroke symptoms and rapid transportation of stroke patients to the closest 
appropriate emergency department for administration of time-dependent therapies 16,17. 
		
Additionally, longer OTT is included in several clinical scores as an independent predictor of 
adverse outcome 18,19 and symptomatic intracerebral hemorrhage (sICH) 20, and newer 
studies have focused on institution- and system-wide strategies to decrease OTT durations in 
order to improve patient outcomes 21.  
In addition to decreasing OTT, a number of interventions have been proposed to limit 
sICH after rt-PA therapy, including agents involved in the inflammatory and oxidative stress 
responses, free radical trap compounds, and enzymes involved in membrane remodeling such 
as matrix metalloprotease-9 (MMP9) 22. Cerebral edema is a known mechanism for 
development of sICH after ischemic stroke 22. Edema progresses rapidly in the first 2-3 days 
after an ischemic insult, initially as ionic edema through increased permeability of 
endothelial ion channels and transporters, and later as vasogenic edema through paracellular 
pathways as the integrity of tight junctions which make up the blood-brain barrier (BBB) 
deteriorates 23,24. Loss of BBB integrity precedes development of sICH 23, making BBB 
permeability and brain edema attractive targets for prognostication 25, and opening up novel 
therapeutic options via MMP9 inhibition. 
The MMP9 inhibitor glyburide (glibenclamide), which inhibits sulfonylurea receptor 
(SUR1)-regulated NCCa-ATP channel activity, has been shown to reduce cerebral edema, 
infarct volume and mortality by 50% in a rat model of middle cerebral artery occlusion 
(MCAO) 26. In MCAO rats treated with rt-PA, glibenclamide treatment significantly reduced 
hemispheric swelling and lowered mortality compared to controls, even when glibenclamide 
was administered up to 10 hours after ischemia 27. Additionally, since glyburide is a long-
time antidiabetic agent, retrospective analysis of type 2 diabetic patients with non-lacunar 
acute stroke who were on sulfonylurea found no incidences of sICH in patients with 
		
sulfonylurea in sharp contrast to diabetic patients who did not take the medication 28. Based 
on these data, a multicenter phase II trial Glyburide Advantage in Malignant Edema and 
Stroke (GAMES) is currently underway to investigate the effect of IV glyburide on sICH in 
patients with severe anterior circulation ischemic stroke.   
 Strategies to predict sICH may also improve outcomes after rt-PA administration by 
excluding patients who are predicted to be at high risk for sICH or poor outcomes. sICH 
prediction has been attempted using a number of imaging techniques 22. Non-Contrast Head 
CT focal hypodensity has been proposed 29, but suffers from difficulties in defining the 
boundaries of the lesion. CT angiography has also been used to measure contrast opacity and 
to develop a clot burden score, which correlates with hypo-perfusion and parenchymal sICH 
30. sICH characterization was attempted in one study using prospective CT scans in ischemic 
stroke patients 4 weeks after stroke 31. sICH occurred in 43% of cases, with most sICH cases 
occurring in the first two weeks after infarct. Other factors that correlated with sICH 
incidence were severe neurological deficit on presentation, disturbance of consciousness, 
cortical involvement and distinct blood/CSF barrier disturbances 31. Additionally, DWI 
sequences on MRI imaging have been used successfuly to correlate sICH with infarct size 
and volume 32.  
Quantitative methodologies have also been employed to assess edema or intracerebral 
hemorrhage volume and its association with clinical outcomes. Volume of spontaneous 
intracerebral hemorrhage has been positively correlated with 30-day mortality, and can 
predict mortality in combination with Glasgow Coma Scale scores with a sensitivity of 96% 
and specificity of 98% 33. A recent small study likewise demonstrated sensitive prediction of 
malignant edema and sICH after ischemic stroke using perfusion CT as a marker for early 
		
BBB permeability 34. Another = study described a CT-based technique for accurately 
measuring edema volume using semi-automated volume reconstruction 35. Using similar 
advanced imaging techniques, it has been demonstrated that cerebral edema independently 
predicts poor outcome after nonlacunar ischemic stroke 36. Volumes of edema and 
intracerebral hemorrhage may therefore be applied as objective measurement tools to predict 
sICH and poor outcome after rt-PA therapy.  
Clinical scores predicting risk of sICH may also enhance therapeutic safety after rt-
PA treatment by identifying select ischemic stroke patients who may receive rt-PA without 
additional risk of sICH. At least 8 clinical risk scores have been developed to predict either 
adverse outcome or sICH after rt-PA therapy. They include the Stroke-Thrombolytic 
Predictive Instrument (Stroke-TPI)37; iSCORE38; Dense cerebral artery or early infarct signs 
on CT, mRS, Age, Glucose level on admission, Onset to treatment time and NIHSS 
(DRAGON) 18; Stroke Prognostication using Age and NIH Stroke Scale-100 (SPAN-100) 39; 
Acute Stroke Registry and Analysis of Lausanne (ASTRAL) 19; Post-thrombolysis Risk 
Score (PRS) 40; Hemorrhage After Thrombolysis (HAT) 41; baseline blood Sugar, Early 
infarct signs, Dense cerebral artery sign, Age and NIHSS (SEDAN) 42; and the Safe 
Implementation of Treatments in Stroke Symptomatic Intracerebral Hemorrhage (SITS-ICH) 
score 20. Several of these scores are computationally complex. An exception is SPAN-100 
which requires only two clinical variables, however it has been reported as a poor predictor 
of sICH in several studies 42-44. Future studies are needed to develop scores that are simple 
but yet accurately predict sICH for widespread clinical applicability. 
 
 
		
Statement of purpose 
Our aim was to objectively evaluate existing scores available for predicting sICH or 
adverse outcome after rt-PA, and to derive a computationally simple but accurate clinical 
score. Our specific aims were as follows: 
1. Comparison of existing scores for predicting post-thrombolysis risk  
2. Derivation and validation of a novel score  
a. Derivation of a novel score 
b. Validation of clinical score in external dataset 
3. Outcome prediction using clinical score 
a. Prediction of brain swelling  
b. Prediction of adverse outcome  
c. Prediction of 90-day mortality  
4. Expansion of clinical utility of score 
  
		
Materials and methods 
Study contributions 
 Study design and clinical data interpretation were done by Dr. Kevin N. Sheth. Data 
collection and clinical data review were done by Karin Nystrom, APRN. Radiological data 
was reviewed by a stroke fellow Hardik Amin, MD. Statistical analyses including data 
presentation and interpretation were performed by myself.   
 
Patient data 
Our internal dataset included all consecutive ischemic stroke patients (n = 210) from 
our dual-center prospective stroke registry who received IV rt-PA therapy from January 2009 
until July 2013 at Yale New Haven Hospital and Yale-New Haven Shoreline Medical Center. 
One patient was excluded due to incomplete data. Eligibility criteria for IV rt-PA treatment 
were applied following the American Heart Association guidelines 17.  
Our external dataset included ischemic stroke patients who received IV rt-PA during 
the NINDA rt-PA Stroke Study, a multicenter, prospective, double-blind, placebo-controlled 
randomized trial from January 1991 to October 1994 7. 9 patients were excluded due to 
incomplete data. Data from the NINDS trial were purchased from the National Technical 
Information Service (NTIS; http://www.ntis.gov/) using internal funds from the Yale 
Department of Neurology. Clinical data was converted to Microsoft Excel format using 
Statistical Analysis System software (SAS Institute Inc, Cary, NC). Individual variables were 
decoded using instructions included in the CD-ROM from NTIS in accordance with 
published guidelines 45.  
		
This study was approved by the Yale Human Investigation Committee and the Yale 
Human Research Protection Program. Written informed consent was not required for 
reviewing retrospective de-identified patient data.    
 
Imaging data:  
Computed tomography (CT) or magnetic resonance imaging (MRI) scans were 
performed in the derivation dataset before IV rt-PA treatment, 24 hours after treatment, and 
subsequent to any observed clinical deterioration. Neuroradiological assessment was 
performed on each patient by a board-certified neurologist (Hardik Amin, MD). CT or MRI 
findings in the validation dataset were reported from a consensus of three neuroradiologists 
blinded to treatment group and outcome as previously published 7. Adverse outcome was 
defined as presence of symptomatic intracerebral hemorrhage (sICH) using the National 
Institute of Neurological Diseases and Stroke (NINDS) rt-PA trial definition 7. sICH status in 
the derivation dataset was determined from documented narratives in the patient’s record.  
 
Outcome measures and clinical scores:  
Severe 90-day outcome was defined according to previously published studies as a 
90-day modified Rankin Scale (mRS) score ≥ 5, a Barthel Index (BI) score < 60 or a 
Glasgow Outcome Scale (GOS) score > 2, and excellent 90-day outcome was defined as a 
90-day mRS score ≤ 1, a BI score ≥ 95 or a GOS score = 1 46-48.  
The prestroke mRS score is an indication of patients’ baseline ability to look after 
themselves in daily life, and measures overall independence with moderate to good inter-
observer reliability 49,50. A score of 0 indicates no symptoms, a score of 5 indicates severe 
		
disability, and a score of 6 indicates death. The admission National Institutes of Health 
Stroke Scale (NIHSS) score measures stroke severity with good inter-observer reliability 
51,52. Both prestroke mRS and NIHSS scores are routinely available at most centers prior to 
the point of rt-PA administration. The Barthel Index measures ability to perform activities of 
daily living after a stroke 53. Patients able to perform all activities of daily living such as 
eating, bathing, walking and using the toilet receive a score of 100. The Glasgow Outcome 
Scale is a global assessment of function 54, and ranges from 1 to 5 with a score of 1 indicating 
mild disability and a score of 5 death. 
We calculated eight predictive scores for each patient: Stroke-Thrombolytic 
Predictive Instrument (Stroke-TPI), Dense cerebral artery or early infarct signs on CT, mRS, 
Age, Glucose level on admission, Onset to treatment time and NIHSS (DRAGON), Stroke 
Prognostication using Age and NIH Stroke Scale-100 (SPAN-100), Acute Stroke Registry 
and Analysis of Lausanne (ASTRAL), Post-thrombolysis Risk Score (PRS), Hemorrhage 
After Thrombolysis (HAT), baseline blood Sugar, Early infarct signs, Dense cerebral artery 
sign, Age and NIHSS (SEDAN) and Safe Implementation of Treatments in Stroke 
Symptomatic Intracerebral Hemorrhage (SITS-ICH). Detailed derivations of each score have 
been published elsewhere 19,37-42 and summarized in Table 1.  
 
Statistical analysis: 
Clinical parameters were presented as medians with interquartile ranges, as 
proportions, or as means with standard deviations and compared respectively using Mann-
Whitney tests, two-sample tests of proportions or two-sample T-tests after checking for equal 
variance and using Welch’s approximation for degrees of freedom 55. Strength of association 
		
between clinical scores and sICH was quantified using univariable logistic regression 
reporting odds ratios, with clinical scores as independent variables and sICH or 90-day 
outcome as the dependent variable. Goodness of fit or model calibration was assessed using 
Hesmer-Lemeshow χ2 statistics, with P > 0.05 considered a statistically significant indicator 
of goodness-of-fit 56. Predictive accuracy or model discrimination was calculated using areas 
under the receiver operating characteristic curve (AUROC). Standard errors were calculated 
by the DeLong method 57. Sensitivity and specificity were assessed by AUROC analyses and 
by 2x2 table analyses. Agreement between sICH and discharge mRS ≥ 5 was assessed using 
linear weighted kappa, which measures agreement between two raters or metrics after 
excluding the effect of chance 58. Clinical scores were internally validated using the 
nonparametric bootstrap method. This resampling technique draws with replacement, n 
observations from an n observation dataset whereby some of the original observations will 
appear once, some more than once and some not at all, and has been successfully used in 
previous studies predicting post-thrombolysis risk 37. 50-200 replications are generally 
adequate for estimates of standard error, and thus for normal-approximation confidence 
intervals 59. We used 250 replications in this study. Agreement between independent clinical 
scores was assessed using the concordance correlation coefficient, which is similar to the 
Kappa test but for continuous variables 60. P values < 0.05 two-tailed were considered 
statistically significant. GraphPad Prism 6.0 software (GraphPad Software, La Jolla, 
California USA) and MATLAB R2014b (MathWorks, Natick, Massachusetts USA) were 
used for statistical figures. Statistical analyses were performed using STATA 14 I/C software 
package (StataCorp LP, College Station, Texas).   
  
		
Results 
Aim 1: Comparison of existing scores:  
We first compared 8 scores for predicting sICH or poor outcome after rt-PA treatment 
in our internal dataset using AUROC 44. Details of each score are summarized in Table 1, and 
a summary of patient characteristics in our internal and external datasets are summarized in 
Table 2. Despite considerable variability in complexity, we found no significant differences 
in AUROC for predicting sICH between any of the scores (P > 0.05). We therefore set out to 
derive a computationally simple score that retained predictive accuracy.  
 
Aim 2: Derivation and validation of a novel score: 
Aim 2A: Derivation of a novel score: 
 Using univariable logistic regression, we identified clinical parameters associated 
with sICH in our internal dataset (Table 3) 61. Prestroke modified Rankin scale (mRS) scores, 
admission National Institutes of Health stroke scale (NIHSS) scores and platelet count were 
significant predictors of sICH. We combined these three parameters using multivariable 
logistic regression to form a clinical score TURNP (Thrombolysis risk Using mRS, NIHSS 
and Platelets). TURNP predicted sICH with odds ratio (OR) 2.7, 95% CI (1.6 - 4.6), P < 
0.001. Model calibration testing yielded a Hosmer-Lemeshow χ2 of 7.64 using 10 quantiles, 
P = 0.47 demonstrating good calibration. TURNP also demonstrated fair to good model 
discrimination with AUROC 0.78, 95% CI (0.64 - 0.92).  
However in the multivariable TURNP model, platelet count yielded an OR of only 
0.99 with β coefficient < 0.01. Furthermore, platelet counts require blood draws and 
laboratory testing that can introduce costly delays in the hyperacute stroke setting. Therefore 
		
we considered a simpler model using only two parameters: TURN (Thrombolysis risk Using 
mRS and NIHSS). TURN predicted sICH with OR 2.7 (1.5 – 4.9), P < 0.001. Model 
calibration was still good with a Hosmer-Lemeshow χ2 of 5.28 using 10 quantiles, P = 0.73. 
Likewise, model discrimination testing yielded an AUROC of 0.74, 95% CI (0.58 – 0.90), 
Table 4. Therefore for clinical and parsimonious reasons, we continued our analyses using 
the simpler score TURN.  
 
Aim 2B: Validation of clinical score in external dataset: 
 We verified prediction of sICH by TURN using our external dataset 7. TURN 
predicted sICH in the external dataset with OR 1.77, 95% CI (1.08 – 2.91), P < 0.001 and 
AUROC 0.65 (0.54 – 0.77). There was no statistically significant difference in AUROC 
between TURN and six other clinical scores for predicting sICH in the external dataset 
(Figure 1A).  
TURN was developed using the classical case-control approach for identifying 
outcome predictors. We also assessed whether a cohort-based approach would yield 
clinically meaningful results. We distinguished between patients in years with sICH rates 
below the NINDS trial rate of 6.4% (low sICH cohort; 2010, 2011 and 2012) and patients in 
years with sICH rates above 6.4% (high sICH cohort; 2009 and 2013) using our internal 
dataset. sICH occurred in 2 out of 101 patients (2.0%) in the low sICH cohort versus 10 out 
of 109 patients (9.2%) in the high sICH cohort (P = 0.025). We confirmed that there were no 
differences in baseline demographic and clinical characteristics between patients in the low 
sICH cohort and patients in the high sICH cohort.  
		
Patients in the low sICH cohort differed significantly from patients in the high sICH 
cohort in several markers of stroke severity, including percent of patients with visual field 
deficits (38.6% versus 24.8%, P = 0.03), percent with decreased levels of consciousness 
(62.4% versus 39.4%, P < 0.001), percent with hyperdense MCA signs (5% versus 13.8%, P 
= 0.03) and percent with early CT hypodensities (14.9% versus 29.4%, P = 0.01). We did not 
find any other statistically significant differences in stroke outcomes or stroke-associated 
fatalities between the two cohorts. We determined whether these significant differences 
between the patient cohorts could predict sICH in individual patients. We performed 
multivariable logistic regression using sICH as the dependent variable and visual field 
deficits, levels of consciousness, hyperdense MCA signs and early CT hypodensities as 
independent variables. This model predicted sICH with odds ratio 2.72, 95% CI (1.12 - 6.61), 
P = 0.03 but AUROC of 0.66, 95% confidence interval = 0.48 – 0.83. Thus, whereas the 
cohort-based approach shows promise for identifying predictors of sICH, this approach did 
not yield predictive accuracy as high as TURN.  
 
Aim 3: Outcome prediction using clinical score: 
Aim 3A: Prediction of brain swelling using TURN: 
Next we assessed the ability of TURN to predict 24-hour brain swelling 62.  Cerebral 
edema independently predicts poor outcome after nonlacunar ischemic stroke 36, therefore 
predictors of cerebral edema may selectively identify ischemic stroke patients who are at risk 
for poor outcome and who may benefit from additional therapy using anti-edema 
medications.  
		
We first confirmed the association between brain swelling and outcome. We used 
composite brain swelling defined as presence of at least two out of the three measures: 
edema, mass effect and midline shift 36. In univariable analysis, baseline brain swelling was 
associated with sICH, 90-day severe outcome and 90-day mortality. However, after adjusting 
for covariates (baseline NIHSS, prestroke mRS, early CT hypodensity and decreased level of 
consciousness), none of these associations reached statistical significance. Conversely, 24-
hour brain swelling and new swelling at 24 hours were significantly associated with ICH, 
sICH, 90-day severe outcome and 90-day mortality (P < 0.05) and these correlations 
remained statistically significant after adjusting for covariates (baseline NIHSS, admission 
blood glucose, HDMCA, decreased level of consciousness and visual field deficits for 24-
hour swelling; and baseline NIHSS, HDMCA, decreased level of consciousness and visual 
field deficits for new swelling at 24 hours), thus confirming the association between brain 
swelling and adverse outcome.  
Given this association, we investigated clinical parameters associated with adverse 
outcome as potential predictors of 24-hour brain swelling including age, diabetes, admission 
glucose, baseline NIHSS, prestroke mRS, HDMCA, early CT hypodensity, decreased level 
of consciousness and visual field defects. Using univariable logistic regression, admission 
glucose, baseline NIHSS, HDMCA, decreased level of consciousness and visual field deficits 
were significantly associated with 24-hour brain swelling. However, only three of these 
associations remained statistically significant after adjusting for covariates: HDMCA (P = 
0.05), decreased level of consciousness (P = 0.05) and visual field deficits (P < 0.001). These 
three parameters are thus independent predictors of 24-hour brain swelling after IV 
thrombolysis.    
		
Next we investigated whether TURN could predict brain swelling after IV 
thrombolysis. Prediction of baseline brain swelling by TURN did not reach statistical 
significance (OR 2.21, P = 0.07), consistent with our finding that baseline brain swelling was 
not significantly associated with any measures of adverse outcome. Instead, TURN predicted 
24-hour brain swelling (OR 2.5, P < 0.001) and new swelling at 24 hours (OR 2.1, P < 
0.001). To rule out possible contributions of ICH to measures of brain swelling such as mass 
effect and midline shift, we also verified that TURN directly predicted 24-hour edema (OR 
2.5, P < 0.001) and new edema at 24 hours (OR 2.2, P < 0.001) with nearly identical results. 
In patients who did not receive IV thrombolysis, TURN similarly predicted 24-hour brain 
swelling (OR 3.88, P < 0.001) and new swelling at 24 hours (OR 3.49, P < 0.001) but not 
baseline swelling (OR 1.29, P = 0.53) adding robustness to its predictive ability. We further 
assessed for agreement between TURN and 24-hour brain swelling or new brain swelling at 
24 hours using areas under the receiver operating characteristic curve (AUROC) and 
Hosmer-Lemeshow statistics. TURN predicted 24-hour brain swelling with AUROC of 0.69, 
95% CI (0.63, 0.75) and Hosmer-Lemeshow χ2 of 5.14 using 10 groups, P = 0.74 
demonstrating statistically significant agreement. Likewise, TURN predicted new brain 
swelling at 24 hours with AUROC of 0.67, 95% CI (0.61, 0.73) and Hosmer-Lemeshow χ2 of 
6.9 using 10 groups, P = 0.55, confirming modest but statistically significant agreement. 
In order to compare prediction of brain swelling between TURN and existing scores, 
we performed univariable logistic regression and AUROC analyses using TURN and six 
other scores for predicting outcome after IV thrombolysis 44, including Stroke-TPI, 
DRAGON, SPAN-100, ASTRAL, HAT and SEDAN. There was no statistically significant 
difference in AUROC for prediction of baseline brain swelling between TURN and the other 
		
six scores. AUROC for 24-hour brain swelling was also significantly higher for TURN than 
for SPAN-100 (AUROC 0.61, P = 0.05) and SEDAN (AUROC 0.59, P = 0.02). Likewise, 
TURN predicted new brain swelling at 24 hours with an OR greater than DRAGON (OR 
1.32, P = 0.02), SPAN-100 (OR 1.02, P < 0.001), ASTRAL (OR 1.07, P < 0.001) and 
SEDAN (OR 1.21, P = 0.01), and AUROC for TURN was higher than for SEDAN for 
predicting new brain swelling at 24 hours (AUROC 0.56, P = 0.01). None of the other scores 
predicted 24-hour brain swelling or new swelling at 24 hours with odds ratio or AUROC 
higher than TURN (Figure 1B).  
 
Aim 3B: Prediction of adverse outcome using TURN: 
Next we assessed for correlation between sICH and 90-day severe outcome defined as 
mRS ≥ 5, Barthel Index < 60 and Glasgow Outcome Scale > 2 using univariable logistic 
regression with sICH as the independent variable. sICH predicted 90-day mRS ≥ 5 with odds 
ratio 10.1, 95% CI (4.0, 25.6), P < 0.001. sICH also predicted 90-day Barthel Index < 60 with 
odds ratio 12.2, 95% CI (4.1, 36.9), P < 0.001, and Glasgow Outcome Scale > 2 with odds 
ratio 14.5, 95% CI (4.2, 49.7), P < 0.001.  
We verified agreement between sICH and 90-day severe outcome using linear 
weighted Kappa 58. We found 80% agreement between sICH and 90-day mRS ≥ 5, Kappa 
0.27, P < 0.0001, 72% agreement with 90-day Barthel Index < 60, Kappa 0.22, P < 0.0001, 
and 69% agreement with 90-day Glasgow Outcome Scale > 2, Kappa 0.21, P < 0.0001. 
Therefore we established a direct correlation between sICH and 90-day severe outcome, with 
the strongest correlation between sICH and 90-day mRS ≥ 5. 
		
We next assessed the ability of TURN to predict 90-day severe outcome using 
univariable logistic regression. TURN predicted mRS ≥ 5 with odds ratio 5.73, 95% CI (3.60, 
9.10), P < 0.001. Goodness of fit was assessed as Hosmer-Lemeshow χ2 of 3.63 using 10 
groups, P = 0.89, demonstrating good agreement. We found an AUROC of 0.83, 95% CI 
(0.77, 0.89), confirming good overall accuracy.  
We verified the ability of TURN to predict 90-day severe outcome using the Barthel 
Index (BI) and the Glasgow Outcome Score (GOS). TURN predicted 90-day BI < 60 with 
odds ratio 5.07, 95% CI (3.35, 7.67), P < 0.001. Likewise, TURN predicted 90-day GOS > 2 
with odds ratio 5.17, 95% CI (3.42, 7.80), P < 0.001. Goodness of fit analysis yielded a 
Hosmer-Lemeshow χ2 of 7.93 for 90-day BI < 60 using 10 groups, P = 0.44, and Hosmer-
Lemeshow χ2 of 9.0 for 90-day GOS > 2 using 10 groups, P = 0.34, indicating good 
agreement. TURN also predicted 90-day BI < 60 with AUROC of 0.81, 95% CI (0.76, 0.86), 
and GOS > 2 with AUROC of 0.81, 95% CI (0.76, 0.86) verifying good overall accuracy.     
Next we compared TURN to six existing scores for predicting 90-day outcomes. 
TURN predicted 90-day mRS ≥ 5 with AUROC significantly higher than SPAN-100 and 
SEDAN (P < 0.05) (Figure 1F). Similar results were obtained using 90-day BI < 60 and 90-
day GOS > 2 (Figure 1D-E). None of the other scores yielded an AUROC significantly 
higher than TURN, demonstrating its strength of association and predictive accuracy 
compared to existing scores.   
 
Aim 3C: Prediction of 90-day mortality using TURN: 
We also investigated whether TURN predicts 90-day mortality after IV thrombolysis. 
Since TURN predicted 24-hour brain swelling, and 24-hour brain swelling is associated with 
		
90-day mortality, we hypothesized that TURN would predict 90-day mortality. Using 
univariable logistic regression, we found a statistically significant association between 
TURN and 90-day mortality (OR 5.32, P < 0.0001). Agreement was further confirmed by 
AUROC analysis and by Hosmer-Lemeshow statistics. TURN yielded an AUROC of 0.82, 
95% CI (0.76, 0.88), and a Hosmer-Lemeshow χ2 of 2.94 using 10 groups, P = 0.94 
confirming good agreement.  
We further assessed for etiology of 90-day mortality after IV thrombolysis. As 
expected, TURN predicted 90-day cardiovascular mortality (OR 3.84, P < 0.001) and 90-day 
cerebrovascular mortality (OR 3.50, P < 0.001). However, TURN did not predict 90-day 
mortality due to infectious causes (OR 1.52, P = 0.16), indicating specificity in its predictive 
ability.  
We compared the ability of TURN to predict 90-day mortality to the other six scores 
for predicting post-thrombolysis outcome 44. TURN predicted 90-day mortality with an odds 
ratios higher than for DRAGON (OR 2.09, P = 0.02), SPAN-100 (OR 1.09, P = 0.002), 
ASTRAL (OR 1.17, P = 0.002) and SEDAN (OR 2.1, P = 0.02). AUROC for TURN was 
also significantly higher than for SEDAN (AUROC 0.7, P = 0.02, Figure 1C). None of the 
other scores predicted 90-day mortality with odds ratios or AUROC significantly higher than 
TURN. 
  
Aim 4: Expansion of clinical utility of clinical score: 
To improve the clinical utility of TURN, we developed and tested a mobile 
application Risk rtPA based on TURN for predicting 90-day outcome after rt-PA treatment 
63. Risk rtPA requires only prestroke mRS scores and admission NIHSS scores for each 
		
patient, and predicts both severe outcome (90-day mRS ≥ 5) and excellent outcome (90-day 
mRS ≤ 1) using the inverse logit of TURN and –TURN as follows: TURN predictor for 
severe outcome = and –TURN predictor for excellent outcome = . 
TURN and –TURN were calculated as follows: TURN = -4.65 + (mRS * 0.27) + (NIHSS * 
0.10), and –TURN = 4.65 – (mRS * 0.27) - (NIHSS * 0.10). The response of Risk rtPA 
followed an S-shaped pattern over the range of possible prestroke mRS scores and admission 
NIHSS scores as expected from the inverse logit function (Figure 2). Risk rtPA also returned 
predictions of severe outcome for a range of hypothetical patients with varying clinical 
characteristics (Figure 3), demonstrating broad applicability.  
After AUROC analysis and using 2x2 tables, we selected a cutoff of 3.5 for severe 
outcome and a cutoff of 97 for excellent outcome for Risk rtPA. At these cutoffs, Risk rtPA 
predicted severe outcome with sensitivity of 94.4% but specificity of 52.2%, and predicted 
excellent outcome with specificity of 83.9% but sensitivity of 61.2%. These cutoffs were 
chosen to maximize sensitivity for predicting severe outcome and to maximize specificity for 
predicting excellent outcome to ensure that patients deemed safe for rt-PA therapy are at 
minimal risk for sICH and poor outcome. Thus, Risk rtPA brings accurate but 
computationally simple prediction of outcomes using TURN to the bedside, and enables real-
time prediction of 90-day outcome in ischemic stroke patients being evaluated for anti-
thrombolytic therapy.  
 
Testing of supplemental hypotheses: 
We tested whether mRS scores at patient discharge could serve as a clinically useful 
surrogate for long-term outcome 64. First we assessed the correlation between discharge mRS 
eTURN
(1+ eTURN )%
e−TURN
(1+ e−TURN )%
		
scores and sICH. There was 83.4% agreement between patients with sICH and discharge 
mRS ≥ 5 (kappa 0.22, P < 0.001). Next we performed logistic regression and AUROC 
analysis using discharge mRS ≥ 5 as the dependent variable and each of the eight clinical 
scores as independent variables. All clinical scores showed good agreement with discharge 
mRS ≥ 5 (ROC area > 0.7). The two scores showing the best agreement with discharge mRS 
≥ 5 were Stroke-TPI with AUROC 0.86, 95% CI (0.80, 0.94) and ASTRAL with AUROC 
0.85, 95% CI (0.79, 0.93), with odds ratios of 1.3, 95% CI (0.86, 1.73) and 0.17, 95% CI 
(0.12, 0.23) respectively. SPAN-100 showed the least agreement with discharge mRS ≥ 5 
with AUROC 0.71, 95% CI (0.62, 0.79) and odds ratio 2.09, 95% CI (1.30, 2.87). Therefore, 
whereas most clinical scores agreed with discharge mRS, this measure does not show 
sufficient correlation with sICH to warrant routine use as a surrogate measure of long-term 
outcome.  
Another question we addressed was whether the time of treatment impacted outcome 
of ischemic stroke patients receiving rt-PA therapy 65. We defined on- and off-hour patient 
cohorts based on time of symptom onset according to published criteria 66. Briefly, the on-
hour cohort consisted of patients developing symptoms between 8am and 6pm Monday 
through Friday. Patients in the off-hour cohort developed symptoms Monday through Friday 
6pm to 8am, weekends, Memorial Day, Labor Day, Independence Day, Thanksgiving 
(Wednesday 6pm through the following Monday 8am), Christmas (December 24th and 25th) 
and New Year’s Day (December 31st and January 1st). 
Patients in the on-hour cohort were older (mean age 73.3 versus 68.2, P = 0.03), had 
significantly more previous strokes or transient ischemic attacks (TIAs) (27.6% versus 
16.3%, P = 0.05) and had higher average pre-stroke mRS scores (1.0 versus 0.6, P = 0.04) 
		
than off-hour patients. We found no other statistically significant difference in baseline 
clinical characteristics between patients in the on- versus off-hour cohorts.  
On-hour cohort patients did not have a significantly different median onset-to-
treatment time compared to patients in the off-hour cohort (137 minutes versus 145 minutes, 
P = 0.53), nor were there differences in the percentage of patients treated after 3 hours or 
after 4.5 hours (16.1% versus 26%, P = 0.09; and 1.1% versus 4.9%, P = 0.14 respectively). 
We assessed stroke severity between on- and off-hour cohort patients and found no 
significant differences in mean NIHSS scores (12.4 versus 11.3, P = 0.27) or in percentages 
of patients with visual field deficits (34.5% versus 29.3%, P = 0.42), decreased levels of 
consciousness (57.5% versus 45.5%, P = 0.09), early CT hypodensities (26.4% versus 
19.5%, P = 0.24) or the hyperdense MCA sign on imaging (26.4% versus 19.5%, P = 0.24).   
 We also compared clinical outcomes between patients in the on- and off-hour cohorts 
and found no significant differences in the percentage of patients developing ICH (17.2% 
versus 20.3%, P = 0.58) or sICH (4.6% versus 6.5%, P = 0.56). On-hour cohort patients did 
not have significantly different mean change in mRS scores (2.4 versus 2.8, P = 0.16), and 
did not have significantly different mean discharge mRS scores compared to off-hour 
patients (3.4 versus 3.4, P = 0.85). Furthermore, we found no statistically significant 
differences in stroke fatality between the on- and off-hour patient cohorts (9.2% versus 9.8%, 
P = 0.89). Therefore, despite differences in baseline clinical characteristics, there were no 
significant time-dependent differences in stroke severity or outcome in the internal patient 
dataset from our primary stroke centers.  
 
  
		
Discussion 
Development and validation of TURN: 
 In this project we described TURN, a new clinical predictor of sICH, poor outcome 
and 90-day mortality in ischemic stroke patients receiving IV thrombolysis. Despite its 
computational simplicity, TURN predicts outcome with comparable or better accuracy than 
existing scores. We further developed and tested a mobile application Risk rtPA for ready 
assessment of ischemic stroke patients at the bedside.  
 At least six of the clinical scores we evaluated in this series require the baseline 
NIHSS score for their calculation (Table 1). DRAGON also requires the prestroke mRS 
score, therefore it is equivalent to TURN plus four other parameters: age, hyperdense middle 
cerebral artery sign or early CT infarct, blood glucose and symptom onset-to-treatment 
duration 18. The other five clinical scores do not require the prestroke mRS score but rather 
evaluate a number of other baseline parameters such as history of diabetes or blood glucose 
for HAT 41, or early stroke findings such as level of consciousness and visual field deficits 
for ASTRAL 19.  
It is perhaps surprising that TURN predicts outcome as well as or better than some of 
the other scores given its simplicity. The performance of TURN is likely due to its reliance 
on the prestroke mRS score. The prestroke mRS score is influenced by a patient’s age, prior 
stroke, existing comorbidities, physical or mental disabilities and coping mechanisms.  
Interestingly, individual contributors to the prestroke mRS score such as age, hypertension, 
diabetes and prior stroke were not independent predictors of sICH 61. In our view, the 
prestroke mRS score can be considered similarly to frailty as a measure of physiological 
vulnerability or the gestalt of a patient’s biopsychosocial stressors normalized to their ability 
		
to cope with such stressors 67, and teasing out individual comorbidities does not appear to 
increase predictive ability.  
In spite of this, we believe our model can be improved by going beyond the prestroke 
mRS score. The prestroke mRS score suffers from limited interobserver reliability due in part 
to its reliance on patient or family-member narratives which may not be reliably available at 
the time of stroke 68. Other markers of overall function such as the Rockwood frailty index, 
Charlson comorbidity index and need for caregivers have greater interobserver reliability, 
and may increase the predictive ability of our score if substituted for the prestroke mRS 
score. However many of these markers also rely on family narratives which limits their 
utility in the acute stroke setting. Biomarkers such as plasma MMP-9 have been shown to 
correlate with cardiovascular risk factors in the general population 69. Future studies are 
needed to investigate biomarkers as surrogate measures of baseline functional status. 
 
Prediction of brain swelling: 
We demonstrated the ability of TURN to predict 24-hour cerebral edema in ischemic 
stroke patients. Cerebral edema is associated with sICH and poor outcome after ischemic 
stroke. Therefore, clinical scores that predict cerebral edema may be helpful in screening for 
ischemic stroke patients who are at increased risk for poor outcome.  
 Blood-brain barrier (BBB) breakdown occurs early in ischemic stroke, and 
contributes to vasogenic edema. BBB breakdown is primarily due to increased matrix 
metalloproteinase-9 (MMP-9) and cellular fibronectin after ischemic stroke 70. As a result, 
early vessel leakiness has been proposed as a prognostic marker for sICH 71-74. Rt-PA 
administration may further exacerbate BBB leakiness by directly upregulating MMP-9 75,76 
		
and LDL receptor-related protein 77. Indeed, both the NINDS part 1 trial and the ECASS1 
trial reported more brain edema in rt-PA treated patients compared to controls 7,9, suggesting 
that increased cerebral edema occurs by at least two separate mechanisms in ischemic stroke 
patients receiving rt-PA treatment.  
Cerebral edema is associated with poor outcome after rt-PA treatment. It was noted in 
the NINDS rt-PA trial that cerebral edema occurred more frequently in patients with 
intracranial hemorrhage, however this difference was not quantified 7. We elaborated on this 
finding and demonstrated that 24-hour edema including edema at 24 hours not previously 
seen at baseline is independently associated with ICH, sICH, 90-day severe outcome and 90-
day mortality. This result is consistent with studies from our group and others showing that 
cerebral edema independently predicts worse outcome after ischemic stroke 36,78. Ongoing 
efforts seek to address cerebral edema as a therapeutic target using Glyburide, an agent that 
may decrease plasma MMP-9 levels and vasogenic edema in ischemic stroke patients 79.  
Given the association between cerebral edema and poor outcome, it is perhaps not 
surprising that clinical scores developed to predict post-thrombolysis sICH or poor outcome 
also predict 24-hour cerebral edema, albeit modestly. Likewise, the three factors we 
identified after multivariable logistic regression as independent predictors of 24-hour edema 
(HDMCA, decreased level of consciousness and presence of visual field deficits) have 
previously been identified as sICH predictors after IV thrombolysis 80.  
TURN is calculated using prestroke mRS scores and admission NIHSS scores, 
suggesting that these two parameters are associated with development of edema within 24 
hours. The prestroke mRS score indicates a patient’s baseline ability to look after themselves 
in daily life, and shows moderate to good inter-observer agreement 49,50. The admission 
		
NIHSS score measures initial stroke severity and also shows moderate to excellent inter-rater 
reliability 51,81. The link between these two parameters and cerebral edema is currently 
unclear. Plasma MMP-9 levels are independently associated with cardiovascular risk factors 
in the general population 69, and may thus indirectly correlate with baseline functional status. 
Likewise, plasma MMP-9 levels 48 hours after ischemic stroke are significantly associated 
with baseline NIHSS scores 82. Given the potential role of MMP-9 in the pathogenesis of 
cerebral edema, it is tempting to speculate that prestroke mRS scores and baseline NIHSS 
scores are mechanistically linked to development of cerebral edema after ischemic stroke. 
However, neither parameter was independently associated with 24-hour edema in our dataset 
after adjusting for covariates. Further studies are needed to help clarify these findings.  
One limitation of our study is its reliance on CT scans from the 1995 NINDS rt-PA 
trial. Advances in CT technology since the publication of the NINDS rt-PA trial may have 
affected the interpretation of our results. We expect newer CT scanning and reconstruction 
techniques to be more accurate, and markers of brain swelling more readily detected. 
Therefore, any limitations in the CT technology used in the NINDS rt-PA trial would tend to 
bias our results towards the null. Newer scans may show even stronger associations between 
brain swelling and adverse outcome, and TURN may better predict brain swelling as seen on 
newer scans. 
 
Risk rt-PA, a mobile application based on TURN: 
We extended the clinical utility of TURN using a mobile application readily available 
at the bedside. To our knowledge, iSCORE remains the only risk calculator available on the 
iOS platform. We were unable to directly compare iSCORE to TURN in previous studies due 
		
to unavailability of required data. Nevertheless, iSCORE has been estimated in the NINDS 
dataset 83, and was found to predict sICH with higher overall accuracy compared to TURN as 
measured by AUROC (0.75 versus 0.65 for TURN), but lower accuracy for detecting 90-day 
adverse outcome (mRS ≥ 4; AUROC 0.67 versus 0.77 for TURN). iSCORE benefits from 
validation in several large patient datasets 38,84,85. However iSCORE relies on 8 clinical 
parameters including presence of lacunar infarcts and history of renal dialysis, which may not 
be routinely accessible in the acute stroke setting, whereas TURN requires only two readily 
available clinical parameters. Risk rtPA therefore provides a comparatively accurate but 
computationally simpler alternative for estimating risk of severe outcome at the bedside.  
One limitation of Risk rtPA is its non-linear response at extreme values for mRS and 
NIHSS. This is largely due to a limitation of the inverse logit function. The logit function 
forms the basis of model fitting using univariable and multivariable logistic regression. The 
inverse logit function or logistic function describes the probability of an event given 
weighted exposures. It has the same general form as the log odds function from linear 
regression but has a sigmoidal or S-shaped profile ranging from 0 to 1 86. It is therefore not 
surprising that the output of our mobile application becomes increasingly nonlinear as we 
approach the limits of input values. Nevertheless we demonstrated its functionality over a 
wide range of clinically relevant values.   
We based our cutoffs for outcome probabilities on maximal sensitivity for predicting 
severe outcome in order to minimize the number of false negatives, i.e. patients who are 
deemed safe for treatment but experience severe outcome. Likewise, for predicting excellent 
outcome, we preferentially maximized specificity and therefore minimized number of false 
positives, which in this case also means patients who are deemed safe but experience severe 
		
outcome. Therefore, although our objective was to rule-in all eligible patients who may 
receive rt-PA therapy safely, we chose conservative cutoff values in order to maintain a 
sufficient margin of safety.  
 
Study limitations: 
Our study suffers from a number of limitations. It is a retrospective study with 
relatively small sample sizes, which may have limited our ability to detect statistically 
significant differences between the clinical scores we tested. Future studies are needed to 
verify our results using large prospective datasets. Another limitation of our study is our 
singular use of the NINDS trial definition of sICH 7, which may have placed scores derived 
using other sICH definitions at a relative disadvantage 44. However, 3 scores used in our 
study were derived using the NINDS definition 39-41, and this definition captures a greater 
percentage of hemorrhages compared to the European-Australasian Cooperative Acute 
Stroke Study (ECASS) II and SITS-Monitoring Study (SITS-MOST) definitions 87, which 
require more extensive neurological worsening from baseline (i.e. NIHSS ≥ 4 points). A 
recent comparison of sICH definitions found no clear consensus on the best sICH definition 
in terms of predictive value and interrater agreement 87, and other studies comparing clinical 
scores using multiple sICH definitions have found no meaningful differences between their 
results across sICH definitions 43,88.  
 
 
 
 
		
Conclusions and future directions 
 We developed and tested TURN a simple clinical score to predict sICH and poor 
outcome after rt-PA treatment in ischemic stroke patients. A mobile application Risk rtPA is 
available for prognostication at the bedside. A large multicenter prospective study is being 
planned to verify our findings in an independent patient cohort. The study design will be a 
pragmatic randomized clinical trial comparing risk assessment by a clinician alone versus a 
clinician plus the Risk rtPA mobile application in a real-world clinical setting. These results 
may bring Risk rtPA closer to incorporation into routine clinical practice for assessment of 
ischemic stroke patients being evaluated for rt-PA therapy.  
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Tables and figures 
Score Components 
Stroke-TPI Age, NIHSS, Glucose 
DRAGON 
 
Age, prestroke mRS, HDMCA or early CT infarct, glucose, OTT, admission 
NIHSS 
SPAN-100 Age, admission NIHSS 
ASTRAL Age, admission NIHSS, OTT, decreased level of consciousness, visual field 
defects, glucose 
MSS Age, admission NIHSS, glucose, platelets 
HAT DM or glucose, admission NIHSS, early CT hypodensity  
SEDAN Age, NIHSS, glucose, HDMCA sign, early CT infarct 
SITS-ICH Age, weight, hypertension, Aspirin/Clopidogrel, admission NIHSS, systolic BP, 
glucose, OTT 
 
Table 1. Patient characteristics used to derive clinical scores. NIHSS = National Institute of 
Health Stroke Scale score, mRS = modified Rankin Scale, HDMCA = Hyperdense Middle 
Cerebral Artery sign, OTT = Onset To Treatment interval, DM = Diabetes Mellitus, CT = 
Computed Tomography, BP = Blood Pressure. Stroke-TPI = Stroke-Thrombolytic Predictive 
Instrument. SPAN-100 = Stroke Prognostication using Age and NIH Stroke Scale-100. 
ASTRAL = Acute Stroke Registry and Analysis of Lausanne. HAT = Hemorrhage After 
Thrombolysis. 
  
		
  YNHH (n = 210) NINDS (n = 303) P value 
Patient characteristics       
Mean age 70.3 67.5 0.033* 
% Males 48.6 57.1 0.057 
Mean weight (lbs) 181.1 167.9 0.006* 
Mean systolic BP (mmHg) 156.5 159.8 0.183 
% Hypertension 73.8 66.6 0.078 
% on Aspirin  38.6 40.7 0.625 
Mean admission glucose 
(mg/dL) 
133.3 148.9 0.006* 
% Diabetic 23.3 21.9 0.708 
% Previous stroke/TIA 21.9 27.6 0.087 
Median prestroke mRS score 0 0 <0.001* 
Median OTT (mins) 140 90 <0.001* 
Stroke severity       
Median NIHSS score 10 14 <0.001* 
% Visual field deficits 31.4 54.5 <0.001* 
% Decreased LOC 50.5 32.7 <0.001* 
% Hyperdense MCA sign 9.5 88.3 <0.001* 
% Early CT Hypodensities 22.4 8.5 <0.001* 
Stroke outcomes       
% ICH 19.0 15.4 <0.001* 
% sICH 5.7 8.0 0.320 
		
% Fatalities 9.5 2.9 0.001* 
 
Table 2. Demographic and clinical characteristics, stroke severity and outcomes in the 
derivation dataset (YNHH) compared to the external validation dataset (NINDS). P values 
from Mann-Whitney tests, two-sample tests of proportions and two-sample t tests after 
checking for equal variance. * P values < 0.05 two-tailed considered statistically significant. 
TIA = transient ischemic attack, mRS = modified Rankin Scale, OTT = onset-to-treatment 
duration, NIHSS = National Institute of Health Stroke Scale, LOC = level of consciousness, 
MCA = middle cerebral artery, CT = computed tomography, ICH = intracerebral 
hemorrhage, sICH = symptomatic intracerebral hemorrhage. 
 
 
 
 
 
  
		
  Odds ratio 95% Confidence Interval z P > |z| 
Patient characteristics        
Age 1.04 0.99      1.09  1.71 0.09 
Gender 0.33 0.09      1.27 -1.61 0.11 
Hypertension 4.13 0.52     32.72  1.34 0.18 
Aspirin  1.64 0.51      5.27  0.83 0.41 
Diabetes 1.10 0.29      4.24  0.14 0.89 
Previous stroke/TIA 1.72 0.55      5.39  0.92 0.36 
Labs on admission     
Weight (lbs) 1.00 0.98      1.01 -0.67 0.50 
Systolic BP (mmHg) 1.00 0.98      1.02 -0.05 0.96 
Admission glucose (mg/dL) 1.00 0.99      1.01  0.02 0.98 
Platelets (1000/mcL) 0.99 0.98      1.00 -2.05 0.04* 
Prestroke mRS score 1.54 1.09      2.18  2.44 0.02* 
OTT (mins) 0.99 0.98      1.01 -0.96 0.34 
Stroke severity       
NIHSS score 1.13 1.05      1.22  3.08 0.002* 
Visual field deficits 1.10 0.32      3.78  0.15 0.88 
Decreased LOC 2.04 0.60      7.00  1.13 0.26 
Hyperdense MCA sign 3.55 0.88     14.36  1.78 0.08 
Early CT Hypodensities 1.80 0.52      6.27 0.93 0.35 
 
		
Table 3. Results of univariate logistic regression identifying predictors of sICH in the 
derivation dataset. *P values < 0.05 two-tailed considered statistically significant. sICH = 
symptomatic intracerebral hemorrhage, TIA = transient ischemic attack, BP = blood 
pressure, mRS = modified Rankin scale, OTT = onset-to-treatment time, NIHSS = National 
Institute of Health stroke scale, LOC = level of consciousness, MCA = middle cerebral 
artery, CT = computed tomography.  
  
		
 
TURN  
Clinical parameters β coefficients 
Constant term -4.648 
Baseline NIHSS score 0.104 
Prestroke mRS score 0.270 
  
Prediction of sICH  
Odds ratio 2.7 (1.5, 4.9) 
AUROC 0.74 (0.58, 0.90) 
 
 
 
Table 4. Comparison of TURNP and TURN in the derivation dataset: results of multivariate 
logistic regression reporting log-odds ratios (β coefficients). Dependent variable sICH, 
independent variables NIHSS score, prestroke mRS score and platelet count. sICH = 
symptomatic intracerebral hemorrhage, NIHSS = National Institutes of Health Stroke Scale, 
mRS = modified Rankin Scale, TURNP = Thrombolysis risk Using mRS, NIHSS and 
Platelets, TURN = Thrombolysis risk Using mRS and NIHSS. AUROC = area under the 
receiver operating characteristic curve.  
  
TURNP  
Clinical parameters β coefficients 
Constant term -2.346 
Baseline NIHSS score 0.102 
Prestroke mRS score 0.298 
Platelet count -0.0096 
  
Prediction of sICH  
Odds ratio 2.7 (1.6, 4.6) 
AUROC 0.78 (0.64, 0.92) 
		
 
 
 
 
Figure 1. AUROC values for prediction of outcome in the external validation dataset. TURN 
compared to other clinical scores using unequal variance 2-sample T-tests with Welch’s 
approximation for degrees of freedom. * P values < 0.05 two-tailed considered statistically 
significant. AUROC = area under the receiver operating characteristic curve. sICH = 
symptomatic intracerebral hemorrhage. BI = Barthel index. GOS = Glasgow outcome score. 
mRS = modified Rankin scale. TURN = Thrombolysis risk Using mRS and NIHSS. Stroke-
TPI = Stroke-Thrombolytic Predictive Instrument. SPAN-100 = Stroke Prognostication using 
Age and NIH Stroke Scale-100. ASTRAL = Acute Stroke Registry and Analysis of 
Lausanne. HAT = Hemorrhage After Thrombolysis. 
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Figure 2. Expected response curves using Risk rtPA mobile application to predict severe and 
excellent outcome. Severe and excellent outcome defined as 90-day mRS scores ≥ 5 and 90-
day mRS ≤ 1 scores respectively. X-axis prestroke mRS score; Y-axis admission NIHSS 
score; Z-axis TURN or –TURN predictors predicting 90-day outcome. A. Prediction of 
severe outcome for range of prestroke mRS scores and admission NIHSS scores. B. 
Prediction of excellent outcome for range of prestroke mRS scores and admission NIHSS 
scores. mRS = modified Rankin Scale, NIHSS = National Institutes of Health Stroke Scale.  
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Figure 3. Risk rtPA mobile application for predicting 90-day outcome after IV rt-PA therapy. 
A. Inputs are prestroke mRS score and baseline NIHSS score. Outputs are TURN predictor 
for severe outcome and –TURN predictor for excellent outcome. Severe 90-day outcome 
defined as 90-day mRS scores ≥ 5. Excellent outcome defined as 90-day mRS scores ≤ 1. B. 
Hypothetical patient #1 with a prestroke mRS score of 0 and baseline NIHSS score of 6 
received a TURN predictor of 2 a –TURN predictor of 98. C. Hypothetical patient #2 with a 
prestroke mRS score of 5 and baseline NIHSS score of 37 received a TURN predictor of 64 
and a –TURN predictor of 36. mRS = modified Rankin Scale, NIHSS = National Institute of 
Health Stroke Scale.  
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